TapewireFind a company

person · Reporting owner

DOWNEY BRUCE

Disclosed activity across 4 companies

Tapewire entity
89645
SEC CIK
0001237257

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
C4 Therapeutics, Inc.CCCC · Entity 5503DirectorJune 20, 2024June 21, 2024
CARDINAL HEALTH INCCAH · Entity 3014DirectorJune 30, 2023August 08, 2023
MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249DirectorJune 11, 2019June 12, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

C4 Therapeutics, Inc.

Report date June 20, 2024 · Filed June 21, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2034-06-19Direct32,500 Reported balance After 2024-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-20 · Grant · Acquired 32,500 · Balance 32,500

F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

CARDINAL HEALTH INC

Report date June 30, 2023 · Filed August 08, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect52,729 Reported balance After 2022-11-21 transaction · row 1
1 source row

Row 1 · 2022-11-21 · Gift · Disposed 1,200 · Balance 52,729

MELINTA THERAPEUTICS, INC. /NEW/

Report date June 11, 2019 · Filed June 12, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Melinta Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct30,000 Reported balance After 2019-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000

F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MOMENTA PHARMACEUTICALS INC

Report date October 01, 2020 · Filed October 01, 2020

Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2020-10-01 transaction · row 1
1 source row

Row 1 · 2020-10-01 · Disposition to issuer · Disposed 41,844 · Balance 0

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.19 · Expires 2021-06-14Direct0 Reported balance After 2020-10-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.87 · Expires 2022-06-13Direct0 Reported balance After 2020-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.42 · Expires 2023-06-11Direct0 Reported balance After 2020-10-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.16 · Expires 2024-06-12Direct0 Reported balance After 2020-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.18 · Expires 2025-06-10Direct0 Reported balance After 2020-10-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2020-10-01 · Disposition to issuer · Disposed 17,750 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.97 · Expires 2026-06-23Direct0 Reported balance After 2020-10-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2020-10-01 · Disposition to issuer · Disposed 11,000 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20Direct0 Reported balance After 2020-10-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20Direct0 Reported balance After 2020-10-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19Direct0 Reported balance After 2020-10-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23Direct0 Reported balance After 2020-10-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 20, 2024 Filed Jun 21, 2024 16:07 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 32,500 $0.00 Strike: $4.05 $0.00
Disclosure

SEC source: 0001662579-24-000057 · wk-form4_1719000465.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2034-06-19

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Read SEC document
June 15, 2023 Filed Jun 16, 2023 16:24 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 26,000 $0.00 Strike: $3.61 $0.00
Disclosure

SEC source: 0001662579-23-000060 · wk-form4_1686947050.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Read SEC document
November 21, 2022 Filed Aug 8, 2023 23:46 UTC CARDINAL HEALTH INC CAH · Entity 3014 GiftCommon Shares 1,200 $0.00 $0.00
Disclosure

SEC source: 0000721371-23-000052 · wf-form5_169153838293516.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,729

Read SEC document
November 09, 2022 Filed Nov 10, 2022 21:33 UTC CARDINAL HEALTH INC CAH · Entity 3014 GrantCommon Shares 2,308 $0.00 $0.00
Disclosure

SEC source: 0000721371-22-000162 · wf-form4_166811599108843.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,929

F1 · shares: Grant of restricted share units that will vest on November 9, 2023, except if the 2023 Annual Meeting of Shareholders is prior to November 9, 2023, then the restricted share units will vest on the date of the 2023 Annual Meeting of Shareholders.

Read SEC document
June 22, 2022 Filed Jun 23, 2022 16:15 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 23,500 $0.00 Strike: $6.06 $0.00
Disclosure

SEC source: 0001209191-22-038861 · doc4.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,500

Underlying: Common Stock · 23,500 shares

Expires 2032-06-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
November 11, 2021 Filed Nov 15, 2021 13:11 UTC CARDINAL HEALTH INC CAH · Entity 3014 GrantCommon Shares 3,709 $0.00 $0.00
Disclosure

SEC source: 0000721371-21-000134 · wf-form4_163698188805846.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,621

F1 · shares: Grant of restricted share units that will vest on November 11, 2022, except if the 2022 Annual Meeting of Shareholders is prior to November 11, 2022, then the restricted share units will vest on the date of the 2022 Annual Meeting of Shareholders.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 16:16 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 23,500 $0.00 Strike: $37.66 $0.00
Disclosure

SEC source: 0001209191-21-041421 · doc4.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,500

Underlying: Common Stock · 23,500 shares

Expires 2031-06-14

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2022 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
November 09, 2020 Filed Nov 10, 2020 21:39 UTC CARDINAL HEALTH INC CAH · Entity 3014 GrantCommon Shares 3,339 $0.00 $0.00
Disclosure

SEC source: 0000721371-20-000156 · wf-form4_160504438095364.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,912

F1 · shares: Grant of restricted share units that will vest on November 9, 2021, except if the 2021 Annual Meeting of Shareholders is prior to November 9, 2021, then the restricted share units will vest on the date of the 2021 Annual Meeting of Shareholders.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries B Preferred Stock · Derivative 2,128,571 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027695 · doc4.xml · derivative · entry 4

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 252,394 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries A Preferred Stock · Derivative 2,000,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027695 · doc4.xml · derivative · entry 3

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 237,148 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 252,394 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027695 · doc4.xml · nonDerivative · entry 2

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 489,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 237,148 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027695 · doc4.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $38.09 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 11

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2030-06-23

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $12.64 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 10

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2029-06-19

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 8,855 Not disclosed Strike: $22.30 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 9

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,855 shares

Expires 2028-06-20

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 11,207 Not disclosed Strike: $17.20 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 8

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,207 shares

Expires 2027-06-20

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 11,000 Not disclosed Strike: $10.97 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 7

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,000 shares

Expires 2026-06-23

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 17,750 Not disclosed Strike: $22.18 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 6

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,750 shares

Expires 2025-06-10

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 17,750 Not disclosed Strike: $13.16 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 5

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,750 shares

Expires 2024-06-12

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 17,750 Not disclosed Strike: $14.42 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 4

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,750 shares

Expires 2023-06-11

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 17,750 Not disclosed Strike: $14.87 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 3

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,750 shares

Expires 2022-06-13

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerStock Option (Right to Buy) · Derivative 17,750 Not disclosed Strike: $18.19 Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · derivative · entry 2

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,750 shares

Expires 2021-06-14

F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Read SEC document
October 01, 2020 Filed Oct 1, 2020 17:10 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Disposition to issuerCommon Stock 41,844 Not disclosed Not disclosed
Disclosure

SEC source: 0001179110-20-010059 · edgar.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 21:00 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 17,786 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-027445 · doc4.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,786

Underlying: Common Stock · 17,786 shares

Expires 2030-09-30

F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
June 23, 2020 Filed Jun 24, 2020 17:47 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $38.09 $0.00
Disclosure

SEC source: 0001179110-20-007758 · edgar.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-06-23

F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 17:51 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $12.34 $0.00
Disclosure

SEC source: 0001179110-20-007144 · edgar.xml · derivative · entry 3

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2020-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares at the end of each three-month period following the June 10, 2010 grant date, such that the option was fully vested on June 10, 2011.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 17:51 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Tax withholdingCommon Stock 5,746 $32.21 $185,078.66
Disclosure

SEC source: 0001179110-20-007144 · edgar.xml · nonDerivative · entry 2

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,844

Read SEC document
June 05, 2020 Filed Jun 9, 2020 17:51 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionCommon Stock 15,000 $12.34 $185,100.00
Disclosure

SEC source: 0001179110-20-007144 · edgar.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 12, 2019 Filed Nov 13, 2019 21:18 UTC CARDINAL HEALTH INC CAH · Entity 3014 GrantCommon Shares 3,424 $0.00 $0.00
Disclosure

SEC source: 0000721371-19-000148 · wf-form4_157367987960097.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,573

F1 · shares: Grant of restricted share units that will vest on November 12, 2020, except if the 2020 Annual Meeting of Shareholders is prior to November 12, 2020, then the restricted share units will vest on the date of the 2020 Annual Meeting of Shareholders.

Read SEC document
June 20, 2019 Filed Jun 21, 2019 16:17 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionRestricted Stock Unit · Derivative 4,356 $0.00 $0.00
Disclosure

SEC source: 0001179110-19-008026 · edgar.xml · derivative · entry 3

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,356 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date.

F3 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date.

Read SEC document
June 20, 2019 Filed Jun 21, 2019 16:17 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionCommon Stock 4,356 $0.00 $0.00
Disclosure

SEC source: 0001179110-19-008026 · edgar.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 19, 2019 Filed Jun 21, 2019 16:17 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $12.64 $0.00
Disclosure

SEC source: 0001179110-19-008026 · edgar.xml · derivative · entry 2

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-06-19

F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

Read SEC document
June 11, 2019 Filed Jun 12, 2019 13:37 UTC MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 GrantMelinta Restricted Stock Units · Derivative 30,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001461993-19-000032 · wf-form4_156036104257729.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Melinta Common Stock · 30,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.

F1 · derivative.expiration_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.

Read SEC document
March 18, 2019 Filed Mar 20, 2019 16:57 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $8.85 $0.00
Disclosure

SEC source: 0001179110-19-004104 · edgar.xml · derivative · entry 3

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 20,000 shares

Expires 2019-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested as to 8.33% of the underlying shares at the end of each three-month period following the June 11, 2009 grant date, such that the option was fully vested on June 11, 2012.

Read SEC document
March 18, 2019 Filed Mar 20, 2019 16:57 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 SaleCommon Stock 13,000 $14.51 $188,630.00
Disclosure

SEC source: 0001179110-19-004104 · edgar.xml · nonDerivative · entry 2

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,234

F1 · price: This transaction was executed in multiple trades at prices ranging from $14.50 to $14.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
March 18, 2019 Filed Mar 20, 2019 16:57 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionCommon Stock 20,000 $8.85 $177,000.00
Disclosure

SEC source: 0001179110-19-004104 · edgar.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 30, 2018 Filed Dec 3, 2018 17:36 UTC MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $2.12 $0.00
Disclosure

SEC source: 0000899243-18-029964 · doc4.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-10-31

F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest and become exercisable on October 31, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on October 31, 2019.

Read SEC document
November 09, 2018 Filed Nov 13, 2018 22:17 UTC CARDINAL HEALTH INC CAH · Entity 3014 GrantCommon Shares 3,164 $0.00 $0.00
Disclosure

SEC source: 0000721371-18-000117 · wf-form4_154214741790585.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,149

F1 · shares: Grant of restricted share units that will vest on November 9, 2019, except if the 2019 Annual Meeting of Shareholders is prior to November 9, 2019, then the restricted share units will vest on the date of the 2019 Annual Meeting of Shareholders.

Read SEC document
June 20, 2018 Filed Jun 22, 2018 18:02 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionRestricted Stock Unit · Derivative 5,734 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-008970 · edgar.xml · derivative · entry 4

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,734 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date.

F5 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date.

Read SEC document
June 20, 2018 Filed Jun 22, 2018 18:02 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 GrantRestricted Stock Units · Derivative 4,356 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-008970 · edgar.xml · derivative · entry 3

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,356

Underlying: Common Stock · 4,356 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock.

F3 · derivative.exercise_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

F3 · derivative.expiration_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

Read SEC document
June 20, 2018 Filed Jun 22, 2018 18:02 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 GrantStock Option (Right to Buy) · Derivative 8,855 $0.00 Strike: $22.30 $0.00
Disclosure

SEC source: 0001179110-18-008970 · edgar.xml · derivative · entry 2

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,855

Underlying: Common Stock · 8,855 shares

Expires 2028-06-20

F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

Read SEC document
June 20, 2018 Filed Jun 22, 2018 18:02 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 Exercise / conversionCommon Stock 5,734 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-008970 · edgar.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 08, 2017 Filed Nov 9, 2017 22:28 UTC CARDINAL HEALTH INC CAH · Entity 3014 GrantCommon Shares 2,623 $0.00 $0.00
Disclosure

SEC source: 0000721371-17-000153 · wf-form4_151026650886565.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,985

F1 · shares: Grant of restricted share units that will vest on November 8, 2018, except if the 2018 Annual Meeting of Shareholders is prior to November 8, 2018, then restricted share units will vest on the date of the 2018 Annual Meeting of Shareholders.

Read SEC document
June 20, 2017 Filed Jun 22, 2017 16:15 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 GrantRestricted Stock Units · Derivative 5,734 $0.00 $0.00
Disclosure

SEC source: 0001179110-17-009454 · edgar.xml · derivative · entry 2

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,734

Underlying: Common Stock · 5,734 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock.

F3 · derivative.exercise_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

F3 · derivative.expiration_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

Read SEC document
June 20, 2017 Filed Jun 22, 2017 16:15 UTC MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 GrantStock Option (Right to Buy) · Derivative 11,207 $0.00 Strike: $17.20 $0.00
Disclosure

SEC source: 0001179110-17-009454 · edgar.xml · derivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,207

Underlying: Common Stock · 11,207 shares

Expires 2027-06-20

F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Mr. Downey's continued service to the Company.

Read SEC document
November 03, 2016 Filed Nov 7, 2016 13:21 UTC CARDINAL HEALTH INC CAH · Entity 3014 GrantCommon Shares 2,447 $0.00 $0.00
Disclosure

SEC source: 0000721371-16-000347 · wf-form4_147852486150264.xml · nonDerivative · entry 1

DOWNEY BRUCE · CIK 0001237257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,362

F1 · shares: Grant of restricted share units that will vest on November 3, 2017, except if the 2017 Annual Meeting of Shareholders is prior to November 3, 2017, then the restricted share units will vest on the date of the 2017 Annual Meeting of Shareholders.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.